Cole D. Davidson
Research Subjects
Research Interests
Cole D. Davidson has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Eric L. Bolf
25 shared publications- Frances E. Carr
Department of Pharmacology, Larner College of Medicine, University of Vermont , Burlington, VT 05405
25 shared publications Jennifer A. Tomczak
25 shared publicationsLauren Cozzens
25 shared publications- Noelle E. Gillis
University of Minnesota
25 shared publications Princess D. Rodriguez
25 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T3-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1–STAT1 pathway as a novel, T3-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers.Implications:TRβ-T3 induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T3-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1–STAT1 pathway as a novel, T3-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers.Implications:TRβ-T3 induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 8: Reintroduction of TRβ Increased Expression of interferon/JAK1/STAT1 Pathway Effectors. A-C) Following 24 hours of treatment with T3 or vehicle, protein levels in SW-EV and SW-TRβ were assessed by western blot. TRβ induced expression of JAK1 and STAT1. Representative western blot depicted. (*p<0.05, n=6) D) STAT1 and IRF1 regulated genes were induced upon overexpression of TRβ and T3 treatment. (n=6, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 8: Reintroduction of TRβ Increased Expression of interferon/JAK1/STAT1 Pathway Effectors. A-C) Following 24 hours of treatment with T3 or vehicle, protein levels in SW-EV and SW-TRβ were assessed by western blot. TRβ induced expression of JAK1 and STAT1. Representative western blot depicted. (*p<0.05, n=6) D) STAT1 and IRF1 regulated genes were induced upon overexpression of TRβ and T3 treatment. (n=6, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 2: TRβ Repressed PI3K Signaling. A-I) Expression of cluster 1 differentially expressed genes in the ILK signaling IPA pathway. All genes were repressed by T3 and the level of most of these genes was repressed in the SW-TRβ-T3 condition compared to SW-EV-T3. (n=3, * p0.05) B) AKT phosphorylation was repressed upon overexpression of TRβ in SW1736 cells. (representative blot of 3 experiments).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 2: TRβ Repressed PI3K Signaling. A-I) Expression of cluster 1 differentially expressed genes in the ILK signaling IPA pathway. All genes were repressed by T3 and the level of most of these genes was repressed in the SW-TRβ-T3 condition compared to SW-EV-T3. (n=3, * p0.05) B) AKT phosphorylation was repressed upon overexpression of TRβ in SW1736 cells. (representative blot of 3 experiments).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 4: TRβ Regulates Expression of lncRNAs in ATC Cells. A) A pairwise comparison between SW-EV-T3 and SW-TRβ-T3 reveals differential expression of both mRNAs and lncRNAs (log2(foldchange)>2 and p<0.05). A total of 350 mRNAs and 28 lncRNAs were differentially expressed. B) Expression levels of the differentially expressed lncRNAs in transcripts per million reads.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 4: TRβ Regulates Expression of lncRNAs in ATC Cells. A) A pairwise comparison between SW-EV-T3 and SW-TRβ-T3 reveals differential expression of both mRNAs and lncRNAs (log2(foldchange)>2 and p<0.05). A total of 350 mRNAs and 28 lncRNAs were differentially expressed. B) Expression levels of the differentially expressed lncRNAs in transcripts per million reads.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 7: Reintroduction of TRβ Increased Markers of Thyroid Differentiation. Thyroid differentiation markers were significantly induced in SW-TRβ cells treated with T3 (n=3, * p<0.05).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 7: Reintroduction of TRβ Increased Markers of Thyroid Differentiation. Thyroid differentiation markers were significantly induced in SW-TRβ cells treated with T3 (n=3, * p<0.05).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 1: TRβ Repressed PI3K Signaling. A) Endogenous expression of TRβ is greater in KTC-2 cells than in SW1736. B-C) ATC cell lines were treated with T3 for up to 8 days to measure cell counts. D) Growth kinetics of KTC-2 cells were significantly altered by T3 treatment as determined by area under the curve (AUC). n=3, * p<0.05.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 1: TRβ Repressed PI3K Signaling. A) Endogenous expression of TRβ is greater in KTC-2 cells than in SW1736. B-C) ATC cell lines were treated with T3 for up to 8 days to measure cell counts. D) Growth kinetics of KTC-2 cells were significantly altered by T3 treatment as determined by area under the curve (AUC). n=3, * p<0.05.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 6: TRβ Induced a more Differentiated Phenotype. RNA-sequencing data revealed statistically significant increase of the epithelial marker CDH1 and repression of the mesenchymal marker VIM. Although SNAI1 was expressed, no significant changes in expression were observed. n=3, * p<0.05, ***** p<0.0001.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 6: TRβ Induced a more Differentiated Phenotype. RNA-sequencing data revealed statistically significant increase of the epithelial marker CDH1 and repression of the mesenchymal marker VIM. Although SNAI1 was expressed, no significant changes in expression were observed. n=3, * p<0.05, ***** p<0.0001.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 3: RNA-sequencing of the TRβ-Regulated Transcriptome Reveals a Transcription Factor Network. A) Chromatin Enrichment Analysis (ChEA) of differential expression clusters was performed to evaluate which transcription factor networks were overrepresented in each cluster. B) Multiple transcription factors elucidated by ChEA were also differentially expressed.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 3: RNA-sequencing of the TRβ-Regulated Transcriptome Reveals a Transcription Factor Network. A) Chromatin Enrichment Analysis (ChEA) of differential expression clusters was performed to evaluate which transcription factor networks were overrepresented in each cluster. B) Multiple transcription factors elucidated by ChEA were also differentially expressed.